益筋方治疗重症肌无力的实验研究
|
摘要
目的:探讨温肾活血、益气升清的益筋方对实验性自身免疫性重症肌无力小鼠的治疗机理。方法:用重症肌无力病人的血清被动免疫小鼠,建立实验性自身免疫性重症肌无力模型,针对MG的基本病机是脾肾阳虚兼有血瘀组成益筋方,用益筋方、强的松给小鼠灌胃21天,处死动物。利用流式细胞技术和免疫组织化学方法,分别以T细胞及其亚群为指标,观察益筋方、强的松对EAMG细胞免疫的影响;以IL-2、IL-6、TNF-α为指标,观察益筋方对EAMG细胞因子的影响;通过检测胸腺细胞Bcl-2的表达,观察益筋方对EAMG胸腺的影响。结果:强的松、益筋方均能升高CD3~+,降低CD4~+/CD8~+比值;降低IL-2,降低胸腺Bcl-2表达;对IL-6影响不明显;可升高TNF。结论:益筋方能改善EAMG的肌无力症状,通过影响T细胞和其亚群及细胞因子,调控细胞免疫和体液免疫,起到治疗MG的作用。
Objective: the research studied the mechanism of Yi Jin Prescription with function of warming the kidney, promoting blood circulation, supplementing Qi and raising lucid Yang Qi of treating the mice myasthenia gravis(MG) caused by the disease of autoimmunity. Method: C57BL/6 mice were passively transferred by injected intraperitoneally with plasma of myasthenia gravis .According to the MG pathogenesis of deficiency of the kidney and spleen and blood stasis, the Yi Jin Prescription was made. Mice were administered by prednisone and Yi Jin Prescription ,and killed after 3 weeks.By using the flowcytometric analysis and immunohistochemical technique, the effects of the Yi Jin Prescription and prednisone on the T lymphocyte and T lymphocyte subgroups of the EAMG of mice were observed respectively. The effect of Yi Jin Prescription and prednisone on the EAMG lymphocyte factors was observed by examining the index of TL-2,TL-6 AND TNF-α.The effect of Yi Jin Prescription and prednisone on the thymus was investigated by examining the expression of Bcl-2 of thymus cells. Results: the ratio of CD3~+was higher than the control group and the model group obviously; the ratio of CD4~+ and CD8+were lower significantly than the control group and the model group; the ratio CD4/CD8 was decreased significantly than the control group and the model group. the level of IL-2 was lower than the control group and the model group obviously. the level of IL-6 has no obvious difference with control group; the level of TNF was higher than control group and model group ;the expression of Bcl-2 was lower than the control group and the model group. Conclusions: Yi Jin Prescription can improve the lack strength of muscles and regulate the T lymphocyte and antibody immunological function through impacting on the T lymphocyte and T lymphocyte subgroup and cell factor to treat MG.
Objective: the research studied the mechanism of Yi Jin Prescription with function of warming the kidney, promoting blood circulation, supplementing Qi and raising lucid Yang Qi of treating the mice myasthenia gravis(MG) caused by the disease of autoimmunity. Method: C57BL/6 mice were passively transferred by injected intraperitoneally with plasma of myasthenia gravis .According to the MG pathogenesis of deficiency of the kidney and spleen and blood stasis, the Yi Jin Prescription was made. Mice were administered by prednisone and Yi Jin Prescription ,and killed after 3 weeks.By using the flowcytometric analysis and immunohistochemical technique, the effects of the Yi Jin Prescription and prednisone on the T lymphocyte and T lymphocyte subgroups of the EAMG of mice were observed respectively. The effect of Yi Jin Prescription and prednisone on the EAMG lymphocyte factors was observed by examining the index of TL-2,TL-6 AND TNF-α.The effect of Yi Jin Prescription and prednisone on the thymus was investigated by examining the expression of Bcl-2 of thymus cells. Results: the ratio of CD3~+was higher than the control group and the model group obviously; the ratio of CD4~+ and CD8+were lower significantly than the control group and the model group; the ratio CD4/CD8 was decreased significantly than the control group and the model group. the level of IL-2 was lower than the control group and the model group obviously. the level of IL-6 has no obvious difference with control group; the level of TNF was higher than control group and model group ;the expression of Bcl-2 was lower than the control group and the model group. Conclusions: Yi Jin Prescription can improve the lack strength of muscles and regulate the T lymphocyte and antibody immunological function through impacting on the T lymphocyte and T lymphocyte subgroup and cell factor to treat MG.
引文
[1] 许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000,119.
[2] Simpson JA.Myasthenia gravis:A new hypothesis[J].Scott Med J,1960;(5):419-436.
[3] Rash JE,Albuquerque EX,Hudson CS, et al.Studies of human myasthenia gravis:electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylchdine receptor complex[J].Proc Natl Acad Sci USA,1976;73:4584-4588.
[4] Fambrough DM,Drachman DB,Satyamurtis.Neuromuscular junction in myasthenia gravis:decreased acetylchdine receptors [J].Science,1973;182:293-295.
[5] Engel AG,Lambert EH,Howard FM.Immune complexes(IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations [J].Mayo Clin Proc,1977;52:267-280.
[6] DB.Myasthenia gravis [J].N Engl J Med,1994;330(25):1797-1810.
[7] Ciafaloni E,Sanders DB.Advances in myasthenia gravis[J].Curr Neurol Neurosci Rep,2002;2(1):89.
[8] 黄如训,梁秀玲,刘焯霖,等.临床神经病学[M],北京:科学技术出版社,1999,416-417.
[9] Im SH,Barch D,Feferman T,et al.Protective molecular mimicry in experimental myasthenia gravis[J].J Neuroimmunol,2002;126(1-2):99-106.
[10] Vincent A,Willcox N,Hill M, et al.Determinant spreading and immune responses to acetylchdine receptors in myasthenia gravis [J]. Immunol Rev,1998;164:157-168.
[11] Sims GP,Shiono H, Willcox N, et al.Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylchdine receptors in myasthenia gravis [J].J Immunol,2001;167(4):1935-1944.
[12] Stacy S,Gelb BE,Koop BA,et al.Split tolerance in a novel transgenic model of autoimmune myasthenia gravis[J].J Immunol,2002;169(11):6570-6579.
[13] Paas-Rcener M,Sela M,Mces E.The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual afterred peptide ligand administered by different routes[J].Proc Natl Acad Sci USA,2001;98(22):12642-12647.
[14] Scott BG,Yang H,Tuzun E,et al.ICOS is essential for the development of experimental autoimmune myasthenia gravis[J].Neu mimmunol,2004;153:16-25.
[15] Lindstrom JM.Acetylchdine receptors and myasthenia[J].Muscle Nerve,2000 ;23:453-477.
[16] De Baets M,Stassen MHW.The role of antibodies in myasthenia gravis[J].Neurol Scl,2002;202:5-11.
[17] Mossman S,Vincent A,Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody:a distinct disease entlty [J].Lancet,1996;1:116-119.
[18] Karni A,Zisman E,Katz-Levy Y,et al.Reactivity of T cells from seronegative patients with myasthenia gravis to T cells of the human acetylcholine receptor [J]. Neurology,1997;48:1638-1642.
[19] Soliven BC,Lange DJ,Penn AS,et al. Seronegative myasthenia gravis[J]. Neurology,1988;38(4):514-517.
[20] Kuks TB,Limburg PC,Horst G,et al.Antibodies to skeletal muscle in myasthenia gravis.Part2.Prevalence in non-thymoma patients[J]. Neurol Sci,1993;120(1):78-81.
[21] Bufler J,Pitz R,Czep M,et al.Purified IgG from seropositive and seronegative with patients with myasthenia gravis reversibly blocks currents through nicotinine acetylcholine receptor channels[J].Ann Neurol,1998;43(4):458-464.
[22] Oosterhuis HJ,Kuks JB,et al.Myasthenia gravis syndromes[J].Curr Opin Neurol Neurosurg,1992;5(5):638-644.
[23] Christadoss P,Lindstrom JM,Talal N,et al.Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymphocytes of myastheniac mice[J].Immunol,1986 ;137(6):1845-1849.
[24] 王炜,吕传真,肖保国. 重症肌无力四种突触前后膜结合蛋白抗体的检测[J].中国神经精神疾病杂志,1996;22(3):132-134.
[25] 赖祥青,杨明山.重症肌无力患者免疫发病机制的研究[J].中国病理生理杂志,2001;17(7):662.
[26] Xu TH,Ding J,Shi YL,et al.Effects of myasthenia gravis patients sera with different antibodies on slow k+ current at mouse motor nerve teminals[J].Neurol Res,2003;25:58-62.
[27] Landska DJ.Diagnosis of thymoma in myasthenics using autrstrinted antibodies:predictive value and gain in diaguostic certainty[J].Neurology,1991;41:520-524.
[28] Yamamoto AM,Gajdos P,Eymard B,et al.Anti-titin antibodies in myasthenia gravis:tight association with thymoma and heterogeneity of nonthymoma patients[J].Arch Neurol,2001;58:885-890.
[29] 都爱莲,任惠民,吕传真.重症肌无力发病的非乙酰胆碱受体抗体机制[J].中华神经科杂志,2003;36(1):57.
[30] Mohan S,Barohn RJ,Krolick KA.Unexpected crossreacting between myosin and a main immunogenic region(MIR) of the Acetycholine receptor by antisera obtained from myasthenia gravis patients[J].Clin Immunol Immunopath,1994;70:266.
[31] Hoch W,McConvile J,Helms S,et al. Auto-antibodies to the receptor tyrosine kinas MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies[J].Nat Med,2001;7:365-368.
[32] Evoli A,Tonali PA,Padua L,et al.Clinical correlates with anti- MuSK antibodies in generalized seronegetive myasthenia gravis[J].Brain,2003;126:2304-2311.
[33] McConvile J,Farrugia ME,Beeson D,et al.Detection and characterization of MuSK antibodies in seronegative myasthenia gravis[J].Ann Neurol,2004;55:580-584.
[34] Sanes JR,Lichtman JW.Development of the vertebrate neuromuscular junction[J].Annu Rev Neurosci,1999;22:389-442.
[35] Inoue M,Fulli Y,Okmura M,et al.Mature CD4 simge positive thymocyte in human thymama:T cell may differentiate in the thymic epithelial cell tumor pathohiology.Neurology,1997;65:216-222.
[36] Rapoport B,Portolano S,Mclachlan SM,et al.Combinational libraries:new insight into organ-specific autoantibodies[J].Immunol Today,1995;16:43-49.
[37] Melms A,Schalka BCG,Kirchner TH,et al.Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specified for the nicotinic acetylcholine receptor from thymus of myasthenia gravis[J]. J Clin Invest,1988;81:902-908.
[38] Machl M.Subsets of peripheral blood lymphocytes ,and thymic lymphoid cells in MG.Analysis by fluorocytometry with monoclonal antibodies[J].Fukuka IgakuZasshi,1986;77:241-252.
[39] 周鸣生,陈平,龚其美,等.重症肌无力患者 T 细胞亚群的测定[J].华西医科大学学报,1990;21:298-300.
[40] 许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000,107.
[41] 许蕾,朱一飞,哈志远. 重症肌无力患者细胞免疫水平的检测及临床意义[J]. 脑与神经疾病杂志,2002;10(4);222.
[42] 孙宏,郭红,许贤豪,等.重症肌无力患者外周血乙酰胆碱受体特异性 T 细胞 s IL-2R、IFN-γ、IL-4d 的表达和转录[J].中华神经科杂志,1998;31:79-82.
[43] Huang D,Pirkanen R,Hielmstrom P,et al.Polymorphisms in IL-1 beta and IL-1 receptor antagonist genes are associated with myasthenia gravis[J].Neuroimmunol,1998;81(1-2):76-81.
[44] Emilie D,Crevon MC,Cohen-Kaminsky,et al.In situ production off interleukins in hyperplastic thymus from myasthenia gravis patients[J].Hum Pathol,1991 ;22(5):461-468.
[45] Utsugisawa K,Nagane Y,Tohgi H.Marked increase in CD44-highly positive cells in hyperplastic thymuses from patients with myasthenia gravis[J].Muscle Nerve,2000;23(4):507-513.
[46] Confalonieri P,Antozzi C.Immune activation in myasthenia gravis : soluble interleukin-2 recceptor ,interferon-gamma and tumor necrosis factor-alpha levels in patients serum[J]. Neuroimmunol,1993;48(1):33-36.
[47] Link H,Xiao BG.Rat model as tool to develop new immunotherapies[J].Immunol Rev,2001;184:117-128.
[48] Asthana D,Fujii Y,Huston CE,et al.Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors[J].Immunol Immunopathol,1993;67(3):240-248.
[49] Weissert R,Melms A,Link H.Altered tumor growth factor beta mRNA expression is associated with thymectomy-related clinial remission in myasthenia gravis[J].Neurol Sci,1997;151(1):49-55.
[50] Shimada K,Kch CS.Yanagisawa N[J].Arerugi,1993;42:934.
[51] Huang DR,Zhou YH,Xia SQ,et al.Markers in the promotor region of interleukin-10(IL-10) gene in myasthenia gravis:implications of divers effects ofIL-10 in the pathogenesis of the disease[J].Neuroimmunol,1999;94:82-87.
[52] Karachunski PI,Ostlie NS,Monfardini C,et al.Absence of IFN-gama or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice[J].J Immunol,2000;164(10):5236-5244.
[53] Moiola L,Galbiati F,Martion G,et al.IL-12 is involved in the induction of experimental autoimmune myasthenia gravis,an antibody-mediated disease.Eur J Immunol,1998;28(8):2487-2499.
[54] Matusevicius D,Navikas V,Palasik W,et al.Tumor necrosis factor,lymphotoxin,linterleukin(IL)6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis[J].J Neuroimmunol,1996;71:191-198.
[55] 王炜,南振鹏.干扰素-γ 对重症肌无力患者自身抗体的调节作用及相关分析[J].中国神经免疫和神经病学杂志,2000;7(4):234-236.
[56] Ragheb S,Lisak RP.The thymus and myasthenia gravis[J].Chest Surg Clin N Am,2001;11(2):311-327.
[57] Castleman B.The pathology of the thymus gland in myasthenia gravis[J].Ann N Y Acad Sci,1996;135(1):496.
[58] Levinson AI,Wheatley LM.The thymus and the pathogenesis of myasthenia gravis[J].Clin Immunol Immunopayhol,1996;78:1-5.
[59] Zweiman B,Levinson AI,Lisak RP,et al.Phenotypic characterization of thymic B lymphocytes in myasthenia gravis[J]. Clin Immunol,1989;9(3):242.
[60] Sommer N,Willcox N,Harcourt GC,et al.Myasthenia thymos and thymoma are selectively enriched in acetylcholine receptor reactive T cells[J].Ann Neurol,,1990;28:312-319.
[61] Fujii Y,Hashimoto J,Monden Y,et al.Specific activation of lymphocytes against acetylcholine receptor in myasthenia gravis[J].J Immunol,1986;136(3):887.
[62] 岳岚,柴莹,沈钢,等.胸腺生发中心及 Bcl-2 蛋白表达水平与获得性自身免疫性重症肌无力的关系[J]. 中国实用内科杂志,2001;21(4):228.
[63] Sommer N,Willcox N Harcourt GC,et al.Myasthenia thymos and thymoma are selectively enriched in acetylcholine receptor reactive T cells[J].Ann Neurol,1990;28:312.
[64] Oosterhuis HJ,Kuks JB.Myasthenia gravis and myasthenic syndromes in the rat[J].Curr Opin Neurol Neurosurg,1992;5(5):638.
[65] Shiono H,Fujii Y,Okumura M,et al.Failure to down regulate Bcl-2 protein in thymic geminal center B cell in myasthenia gravis[J].Eur J Immunol,1997;27(4):805.
[66] Onodera J,Nakamura S,Nagano I,et al.Upregulation of Bcl-2 protein in the myasthenic thymus[J].Ann Neurol,1996;39(4):521
[67] Shiono H,Fujii Y,Okumura M,et al. Failure to down regulate Bcl-2 protein in thymic geminal center B cell in myasthenia gravis[J].Eur J Immunol,1997;27(4):805-809.
[68] 张清勇,赵国强,杜英,等. 重症肌无力患者胸腺组织中 P1O、Bcl-2 和 Fas mRNA的表达[J].郑州大学学报,2005;40(1):8.
[69] 沈钢,柴建,岳岚. 重症肌无力患者胸腺组织中 Bcl-2 和 Fas 表达水平的研究[J].浙江医学,2005;27(6):415-416.
[70] Horiki T,Inoko H,Moriuchi J,et al.Combinations of HLA-DPB1and HLA-DQB1alleles determine susceptibility to early-onset myasthenia gravis in Japan[J].Autoimmunity,1994;19:49-54.
[71] Giraud M,Beaurain G,Eymard B,et al.Genetic control of autoantibody expression in autoimmune myasthenia gravis:role of the self-antigen and of HLA-linked loci[J].Genes Immun,2004;5:398-404.
[72] Donez B,Ozakbas S,Oktem MA,et al. HLA genotypes in Turkish patients with myasthenia gravis:comparison with multiple sclerosis patients on the basis of cilinical subtypes and demographic features.Hnm Immunol,2004;65:752-757.
[73] Shinomiya N,Nomura Y,Segawa M.A variant of childhood-onset myasthenia gravis:HLA typing and clinical characteristics in Japan[J].Clin Imnunol,2004;110:154-158.
[74] Dawkins R.Association between myasthenia gravis and HLA Bw46 ,Bfs,C4A4,C4B2,DR9 in Chinese.In:Bo Duponted[M].Immunobiology of HLA,New York:Springer-verlag,1987,437-439.
[75] 杜可明,张克雄. HLA-Ⅱ基因多肽性与重症肌无力的易感性[J].国外医学遗传学分册,2000;23:11-13.
[76] Garchon HJ.Genetics of autoimmune myasthenia gravis,a model for antibody-meiated autoimmunity in man [J].J Autoimmun,2003;21:105-110.
[77] 许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000,139-151.
[78] 解燕春,李承晏.重症肌无力治疗新进展[J].临床内科杂志,2005;22(6):374-376. [79 ]Richman DP,Agius MA.Treatment of autoimmune myasthenia gravis[J].Neurology,2003;61:1652-1661.
[80] Richman DP,Agius MA. Treatment principles in the management of autoimmune myasthenia gravis[J].Ann NY Acad Sci,2003;998:473-480.
[81] Keesey JC.Clinical evaluation and management of myasthenia gravis[J].Muscle Nerve,2004;29:484-505.
[82] Clafaloni E,Nikhar NK,Massey JM,et al.Retrospective analysis of the use of cyclosporine in myasthenia gravis[J]. Neurology,2000;55:448-450.
[83]龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,44.
[84] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,568-577.
[85] 黄自立.中医百家医论荟萃[M],重庆:重庆出版社,1988,613.
[86] 黄自立.中医百家医论荟萃[M],重庆:重庆出版社,1988,614.
[87] 张介宾.景岳全书[M],上海:上海科学技术出版社,1959,556-558.
[88] 叶天士.临证指南医案[M],上海:上海人民出版社,1959,518-526.
[89] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,78.
[90] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,412.
[91] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,151.
[92] 张慧.痿证论治,重在脾肾-胡建华临床经验[J].上海中医药杂志,1998; (7):7-8.
[93] 林丽,曹惠芬.孟如教授辨治重症肌无力经验举要[J].云南中医学院学报,1998;21(4):34-35.
[94] 陈济东,陈贯一.辨证治疗重症肌无力 216 例[J]. 浙江中医学院学报,2003;27(1):34-35.
[95] 将方建,吴青,陈钢,等.“强力方” 治疗重症肌无力临床观察及对外周血淋巴细胞表型的影响[J]. 上海中医药杂志,1999;(7):9-11.
[96] 段竹联,周增荣.补中益气汤和金匮肾气丸加减治疗重症肌无力之体会[J].现代中医药,2003;(6):48-49.
[97] 徐杰.温运法治疗眼肌型重症肌无力 65 例[J].湖北中医杂志,1988;(4):19-20.
[98] 李忠林.中医药治疗重症肌无力的临床观察[J].天津中医,1996;13(4):21-23.
[99] 韩涛.中西医结合治疗重症肌无力研究探要[J].中医药学刊,2003;21(1):139-140.
[100] 许风全,陈金亮,胡军勇,等.重肌灵系列制剂治疗重症肌无力 300 例[J].中国中医药科技,2001;8(5):333-335.
[101] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,384.
[102] 陈玉春.人参、附子与参附汤免疫调节作用初探[J].中成药,1994;16(8):30-31.
[103] 董群,鲁义东,吴敏毓,等.芪附汤及其组方对阳虚小鼠免疫功能的影响[J].中国实验方剂学杂志,1999;5(3):15-17.
[104] 董淳,徐群英. 芪附汤及其组方对免疫抑制小鼠免疫功能的影响[J].中国中医药信息杂志,2001;8(9):39-41.
[105] 吴伟康.四逆汤方药对注射大剂量氢化可的松大鼠血清 IgG 水平影响的初步观察[J].中医杂志,1988;29(10):59.
[106] 王米渠,严石林,李炜弘,等.寒性中药对 SD 大鼠的实验研究[J].浙江中医学院学报,2002;26(6):43-45.
[107] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,528-530.
[108] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,537-539.
[109] 梁华平,张艳.黄芪多糖调节创伤小鼠白介素 2 及白介素受体基因表达的实验研究[J].中医药学报,1995;(3):27.
[110] 洪介民,邱健行,胡祖光.黄芪多糖在体外对小鼠粒巨噬细胞系祖细胞的影响[J]. 中医药学报,1997;(6):44.
[111] 冯浚志,赵国平.当归的免疫药理研究进展[J].福建中医药,2003;34(3):49-51.
[112] 冯景奇,柳钟勋,左增艳,等.当归多糖及当归内酯对小鼠细胞免疫功能的影响[J].中国免疫学杂志,1998;14(4):279-282.
[113] 刘景田,党小军,张洁.中药多糖增强淋巴细胞免疫效应与机制研究[J]. 中国药学杂志,1999;34(12):807-809.
[114] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,542.
[115] 中华人民共和国药政管理局.现代实用本草[M],北京:人民卫生出版社,1997,248.
[116] 王学廷,王建刚,常永超,等.山萸肉对小鼠免疫功能的影响[J].洛阳医专学报,1994;13(3):135.
[117] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,584.
[118] 王浴生,邓文龙,薛春生.中药药理与应用[M],北京:人民卫生出版社,1998,895.
[119] 卞长武,王东荣,郭文来,等.莪术对小鼠免疫功能的影响[J].中国中医药信息杂志,1989;4(2):29.
[120] Osbima M, Pachner AR,Atassi MZ.Molprofile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG susceptible and non- susceptible mouse strains after different periods of immunization with the receptor[J]. Immunology,1994;31(11):833-843.
[121] Lennon VA,Lindstrom JM,Seybold ME,et al.Experimental autoimmune myasthenia:a model 0f myasthenia gravis in rats and guinea pigs[J].J EXP Med,1975 ;141:1365-1372.
[122] Baggi F,Annomm A,Ubiali F,et al.Breakdown of tolerance to a self-peptide of acetylcholine receptor –subumit induces experimental myasthenia gravis in rats[J]. J Immunol,2004;172(4):2697-2703.
[123] Hoedernaekers AC,Verschnuren JJ,Spaas F,et al.Agerelated susceptibility to experimental auoimmune myasthenia gravis:immunolgical and electrophysiological aspecs. Muscle Nerve,1997,20(9):1091-1101.
[124] Lee KW,Lee SH,Kim Hj,et al. Experimental auoimmune myasthenia gravis and CD5+ B lymphocyte expression.J Korean Med Sci,1999,14(1):75-79.
[125] Wang HB,Shi Fd,Li H,et al.Anti CTLA-4 antiody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol,2001,166(10):6430-6436.
[126] Peas-Rozner M,Mozes E.The nature of the active supression of responses associated with experimental auoimmune myasthenia gravis by a dual altered peptide ligad administered by different routes.Proc Natl Acad SciUSA,2001,98(22):12642-12647.
[127] Scelasa,Frost M,Valderrama R,et al.Prevention and treatment of experimental auoimmune myasthenia gravis with anti-rabbit thymcte serum and gammaglobulin in rabbits.Pathobiology,1995,63(3):168-174.
[128] Goluszko E,Hjelmstrom P,Deng C,et al.Lymphotoxiu-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis.J Neuroimmunol,2001;113:109-118.
[129] Vincent A,Jacobson L,Shillitoc P.Response to human acetylcholine receptor α138-167:determinant spreading intiates autoimmunity to self-antigen in rabbits.Immunol lett,1994;39(10):269-275.
[130] 杨丽,程焱.乙酰胆碱受体α亚单位 125-147 段多肽之实验性自身免疫性重症肌无力.中华神经科杂志,2003;36(1):32-34.
[131] Wang ZY,Karachunski PI,Howard JF Jr,et al.Myasthenia gravis in SCID mice grafted with Myasthenia patient lymphocytes.Neurology,1999;52(3):484-497.
[132] Schoubeck S,Padberg F,Hohlfeld R,et al.Transplantation of thymic autoimmune microenvironment to serve combined immunodeficiency mice.A new model of myasthenia gravis.J Clin Invest,1992;90(1):245-250.
[133] 刘降光,王晓辉,张宏,等.实验性自身免疫性重症肌无力动物模型.中国神经免疫和神经病学杂志,2005;12(2):90-93.
[134] 许贤豪.神经免疫学,武汉:湖北科学技术出版社,2000,145.
[135] 龚非力. 基础免疫学,武汉:湖北科学技术出版社,1998,18.
[136] 张栩,孙兆林,从志强,等.重症肌无力病人外周血单个核细胞 TGF-? 及 IL-6水平测定.青岛大学医学院学报,2003;39(4):386-387.
[137] 李罗清,孙圣刚,徐金枝,等.白细胞介素-6 与重症肌无力患者临床特点的关系.临床神经病学杂志,2005;18(1):19-21.
[138]Cohen-Kaminsky S,Devergne O,Delatre Related Articles,et al.Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially in volved in thymic myperplasia.Eur Cytokin Netw,1993;4(2):121-132.
[139] 徐江龙.肿瘤坏死因子与重症肌无力.中国临床神经科学,2004;12(3):326-327.
[140] 姜广建,马立人,王润田,等. 重症肌无力患者 T 细胞亚群和 TNF-α 检测及临床意义.临床荟萃,2002;17(21):246.
[141] 胡军,阮丽荣,张清勇,等. 重症肌无力患者外周血单个核细胞 Fas 及血清 sFas、TNF 检测.郑州大学学报(医学版),2005;40(1):4-6.
[142] 闫晓波,王维治,韩威. 重症肌无力 cICAM-1 及 TNF-α水平的检测.中国神经免疫学和神经病学杂志,2002;9(2):80.
[143] Huang DR,Priskanen R,Matell G,et al.Tumor necrosis factor-alpha polymorphism and secretion in myasthenia gravis.Neuroimmunol,1999;94(1):165-171.
[144] Confalonieri P,Antozzi C,Comelio F,et al.Immune activation in myasthenia gravis:soluble interleukin-2 receptor ,interferon-gamma and tumor necrosis factor-alpha levels in patients serum.J Neuroimmunol,1993;48(1):33-36.
[145] 程卫东,张庆举.血清可溶性白介素-2 受体滴度与重症肌无力肌群受累程度的相关性研究.临床神经科病学杂志,2004;17(4):253-254.
[146] 许良中,杨文涛.免疫组织化学反应结果的判定标准.中国癌症杂志,1996;6(4):229-230.
[147] Gowans JL,Knight.The route of recirculation of lymphocytes in the rat.Proc R Soc London B,1964;159:257.
[148] Naparstek Y,Ben-Nun A,Holosshitz J,et al.T lymphocytelines producing or vaccinating against autoimmune encephalomyelitis(EAE). Functioal activation induces peanut agglutienin rceptors and accumulation in the brain and thymus of line cells.Eur J Immunol,1993,13(5):418.
[149] Naparstek Y,Holoshitz J,Eissenstein S,et al.Effector T lymophocyte line cells in igrate to the thymus and persist there.Nature,1982;300(5889):262.
[1] 许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000;119.
[2] 中国医学科学院皮肤病研究所雷公藤研究小组.雷公藤多甙治疗某些皮肤病的研究.中华皮肤科杂志,1982;15:199.
[3] 李作孝,张泽兰,谭华,等.重症肌无力患者雷公藤多甙治疗后周围血细胞免疫功能变化的研究.四川医学,2001;22(2):124-125.
[4] 李作孝,熊先骥,张泽兰,等. 重症肌无力患者雷公藤多甙治疗前后周围血自然杀伤细胞含量变化的研究.临床神经学杂志,1999;12(4)216-218.
[5] 陈正君. 雷公藤多甙对重症肌无力患者血清 sIL-2R 水平的影响.邯郸医学高等专科学校学报,2001;14(2):95-96.
[6] 李作孝,谭华,熊先骥,等. 雷公藤多甙辅助治疗重症肌无力临床疗效及对血清 IL-6 的影响.中国中西医结合杂志,2002;22(3):175-176.
[7] 徐冬波,蒋方建,李庚和,等.强力方和黄芪治疗实验性自身免疫性重症肌无力的机理.中医药研究,2000;16(2):41-44.
[8] 赖成虹,李作孝,刘广益.苏木免疫抑制作用的研究进展.医学综述,2004;10(10):635-636.
[9] 赖成虹,李作孝,荣本兵,等.苏木醇提物治疗小鼠实验性重症肌无力的研究.中华神经医学杂志,2005;4(7):669-671.
[10] 蒋方建,吴青,陈钢,等.“强力方”治疗重症肌无力临床观察及对外周血淋巴细胞表型的影响.上海中医药杂志,1999;(7):9-11.
[11] 徐冬波,蒋方建,李庚和,等.强力方对实验性自身免疫性重症肌无力细胞因子含量的影响.上海中医药杂志,2000;10:40-43.
[12] 徐冬波,蒋方建,李庚和,等. 强力方和黄芪治疗实验性自身免疫性重症肌无力的机理.中医药研究,2000;16(2):41-44.
[13] 刘萍,张静生,韩波,等.黄芪复方对重症肌无力 IFN-γ及其 mRNA 表达的影响.中医药学刊,2004;22(11):2021-2022.
[14] 刘萍,张静生,郑菲,等.黄芪复方对重症肌无力患者血清乙酰胆碱受体抗体水平的影响.中国神经免疫和神经病学杂志,2005;12(2):76-77.
[15] 许风全,陈金亮,平阳,等.重肌灵片治疗ⅡA 型重症肌无力的临床研究.北京中医药大学学报,2004;11(4):4-8.
[16] 王旭丹,周勇,韩涛,等.重肌灵片对实验性重症肌无力的影响.上海免疫学杂志,2003;23(5):339-342.
[17] 王旭丹,杨颖袁学勤,等.重肌灵片在重症肌无力小鼠模型 T 细胞活化中的作用.现代免疫学,2005;25(5):411-414.
[18] 张志慧,韩涛.重肌灵对大鼠腹腔巨噬细胞吞噬功能以及 IL-1 诱生的影响[J].中医药学刊,2003;21(7):1129-1130.
[19] 王静,周勇,王旭丹,等.中药重肌灵片体内对 EAMG 大鼠 IFN-γ、IL-4、TGF-β水平的影响.中国免疫学杂志,2004;20(1):63-66.
[60] 黄坤强,王灵萍,尚尔寿,等.复肌宁胶囊治疗重症肌无力 70 例临床观察[J].中国中西医结合杂志,1998;18(12):743-744.
[21] 王曙辉,杨明山.温肾健脾益气活血法治疗重症肌无力 52 例[J].新中医,1999;31(5):33-34.
[2] Simpson JA.Myasthenia gravis:A new hypothesis[J].Scott Med J,1960;(5):419-436.
[3] Rash JE,Albuquerque EX,Hudson CS, et al.Studies of human myasthenia gravis:electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylchdine receptor complex[J].Proc Natl Acad Sci USA,1976;73:4584-4588.
[4] Fambrough DM,Drachman DB,Satyamurtis.Neuromuscular junction in myasthenia gravis:decreased acetylchdine receptors [J].Science,1973;182:293-295.
[5] Engel AG,Lambert EH,Howard FM.Immune complexes(IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations [J].Mayo Clin Proc,1977;52:267-280.
[6] DB.Myasthenia gravis [J].N Engl J Med,1994;330(25):1797-1810.
[7] Ciafaloni E,Sanders DB.Advances in myasthenia gravis[J].Curr Neurol Neurosci Rep,2002;2(1):89.
[8] 黄如训,梁秀玲,刘焯霖,等.临床神经病学[M],北京:科学技术出版社,1999,416-417.
[9] Im SH,Barch D,Feferman T,et al.Protective molecular mimicry in experimental myasthenia gravis[J].J Neuroimmunol,2002;126(1-2):99-106.
[10] Vincent A,Willcox N,Hill M, et al.Determinant spreading and immune responses to acetylchdine receptors in myasthenia gravis [J]. Immunol Rev,1998;164:157-168.
[11] Sims GP,Shiono H, Willcox N, et al.Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylchdine receptors in myasthenia gravis [J].J Immunol,2001;167(4):1935-1944.
[12] Stacy S,Gelb BE,Koop BA,et al.Split tolerance in a novel transgenic model of autoimmune myasthenia gravis[J].J Immunol,2002;169(11):6570-6579.
[13] Paas-Rcener M,Sela M,Mces E.The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual afterred peptide ligand administered by different routes[J].Proc Natl Acad Sci USA,2001;98(22):12642-12647.
[14] Scott BG,Yang H,Tuzun E,et al.ICOS is essential for the development of experimental autoimmune myasthenia gravis[J].Neu mimmunol,2004;153:16-25.
[15] Lindstrom JM.Acetylchdine receptors and myasthenia[J].Muscle Nerve,2000 ;23:453-477.
[16] De Baets M,Stassen MHW.The role of antibodies in myasthenia gravis[J].Neurol Scl,2002;202:5-11.
[17] Mossman S,Vincent A,Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody:a distinct disease entlty [J].Lancet,1996;1:116-119.
[18] Karni A,Zisman E,Katz-Levy Y,et al.Reactivity of T cells from seronegative patients with myasthenia gravis to T cells of the human acetylcholine receptor [J]. Neurology,1997;48:1638-1642.
[19] Soliven BC,Lange DJ,Penn AS,et al. Seronegative myasthenia gravis[J]. Neurology,1988;38(4):514-517.
[20] Kuks TB,Limburg PC,Horst G,et al.Antibodies to skeletal muscle in myasthenia gravis.Part2.Prevalence in non-thymoma patients[J]. Neurol Sci,1993;120(1):78-81.
[21] Bufler J,Pitz R,Czep M,et al.Purified IgG from seropositive and seronegative with patients with myasthenia gravis reversibly blocks currents through nicotinine acetylcholine receptor channels[J].Ann Neurol,1998;43(4):458-464.
[22] Oosterhuis HJ,Kuks JB,et al.Myasthenia gravis syndromes[J].Curr Opin Neurol Neurosurg,1992;5(5):638-644.
[23] Christadoss P,Lindstrom JM,Talal N,et al.Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymphocytes of myastheniac mice[J].Immunol,1986 ;137(6):1845-1849.
[24] 王炜,吕传真,肖保国. 重症肌无力四种突触前后膜结合蛋白抗体的检测[J].中国神经精神疾病杂志,1996;22(3):132-134.
[25] 赖祥青,杨明山.重症肌无力患者免疫发病机制的研究[J].中国病理生理杂志,2001;17(7):662.
[26] Xu TH,Ding J,Shi YL,et al.Effects of myasthenia gravis patients sera with different antibodies on slow k+ current at mouse motor nerve teminals[J].Neurol Res,2003;25:58-62.
[27] Landska DJ.Diagnosis of thymoma in myasthenics using autrstrinted antibodies:predictive value and gain in diaguostic certainty[J].Neurology,1991;41:520-524.
[28] Yamamoto AM,Gajdos P,Eymard B,et al.Anti-titin antibodies in myasthenia gravis:tight association with thymoma and heterogeneity of nonthymoma patients[J].Arch Neurol,2001;58:885-890.
[29] 都爱莲,任惠民,吕传真.重症肌无力发病的非乙酰胆碱受体抗体机制[J].中华神经科杂志,2003;36(1):57.
[30] Mohan S,Barohn RJ,Krolick KA.Unexpected crossreacting between myosin and a main immunogenic region(MIR) of the Acetycholine receptor by antisera obtained from myasthenia gravis patients[J].Clin Immunol Immunopath,1994;70:266.
[31] Hoch W,McConvile J,Helms S,et al. Auto-antibodies to the receptor tyrosine kinas MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies[J].Nat Med,2001;7:365-368.
[32] Evoli A,Tonali PA,Padua L,et al.Clinical correlates with anti- MuSK antibodies in generalized seronegetive myasthenia gravis[J].Brain,2003;126:2304-2311.
[33] McConvile J,Farrugia ME,Beeson D,et al.Detection and characterization of MuSK antibodies in seronegative myasthenia gravis[J].Ann Neurol,2004;55:580-584.
[34] Sanes JR,Lichtman JW.Development of the vertebrate neuromuscular junction[J].Annu Rev Neurosci,1999;22:389-442.
[35] Inoue M,Fulli Y,Okmura M,et al.Mature CD4 simge positive thymocyte in human thymama:T cell may differentiate in the thymic epithelial cell tumor pathohiology.Neurology,1997;65:216-222.
[36] Rapoport B,Portolano S,Mclachlan SM,et al.Combinational libraries:new insight into organ-specific autoantibodies[J].Immunol Today,1995;16:43-49.
[37] Melms A,Schalka BCG,Kirchner TH,et al.Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specified for the nicotinic acetylcholine receptor from thymus of myasthenia gravis[J]. J Clin Invest,1988;81:902-908.
[38] Machl M.Subsets of peripheral blood lymphocytes ,and thymic lymphoid cells in MG.Analysis by fluorocytometry with monoclonal antibodies[J].Fukuka IgakuZasshi,1986;77:241-252.
[39] 周鸣生,陈平,龚其美,等.重症肌无力患者 T 细胞亚群的测定[J].华西医科大学学报,1990;21:298-300.
[40] 许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000,107.
[41] 许蕾,朱一飞,哈志远. 重症肌无力患者细胞免疫水平的检测及临床意义[J]. 脑与神经疾病杂志,2002;10(4);222.
[42] 孙宏,郭红,许贤豪,等.重症肌无力患者外周血乙酰胆碱受体特异性 T 细胞 s IL-2R、IFN-γ、IL-4d 的表达和转录[J].中华神经科杂志,1998;31:79-82.
[43] Huang D,Pirkanen R,Hielmstrom P,et al.Polymorphisms in IL-1 beta and IL-1 receptor antagonist genes are associated with myasthenia gravis[J].Neuroimmunol,1998;81(1-2):76-81.
[44] Emilie D,Crevon MC,Cohen-Kaminsky,et al.In situ production off interleukins in hyperplastic thymus from myasthenia gravis patients[J].Hum Pathol,1991 ;22(5):461-468.
[45] Utsugisawa K,Nagane Y,Tohgi H.Marked increase in CD44-highly positive cells in hyperplastic thymuses from patients with myasthenia gravis[J].Muscle Nerve,2000;23(4):507-513.
[46] Confalonieri P,Antozzi C.Immune activation in myasthenia gravis : soluble interleukin-2 recceptor ,interferon-gamma and tumor necrosis factor-alpha levels in patients serum[J]. Neuroimmunol,1993;48(1):33-36.
[47] Link H,Xiao BG.Rat model as tool to develop new immunotherapies[J].Immunol Rev,2001;184:117-128.
[48] Asthana D,Fujii Y,Huston CE,et al.Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors[J].Immunol Immunopathol,1993;67(3):240-248.
[49] Weissert R,Melms A,Link H.Altered tumor growth factor beta mRNA expression is associated with thymectomy-related clinial remission in myasthenia gravis[J].Neurol Sci,1997;151(1):49-55.
[50] Shimada K,Kch CS.Yanagisawa N[J].Arerugi,1993;42:934.
[51] Huang DR,Zhou YH,Xia SQ,et al.Markers in the promotor region of interleukin-10(IL-10) gene in myasthenia gravis:implications of divers effects ofIL-10 in the pathogenesis of the disease[J].Neuroimmunol,1999;94:82-87.
[52] Karachunski PI,Ostlie NS,Monfardini C,et al.Absence of IFN-gama or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice[J].J Immunol,2000;164(10):5236-5244.
[53] Moiola L,Galbiati F,Martion G,et al.IL-12 is involved in the induction of experimental autoimmune myasthenia gravis,an antibody-mediated disease.Eur J Immunol,1998;28(8):2487-2499.
[54] Matusevicius D,Navikas V,Palasik W,et al.Tumor necrosis factor,lymphotoxin,linterleukin(IL)6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis[J].J Neuroimmunol,1996;71:191-198.
[55] 王炜,南振鹏.干扰素-γ 对重症肌无力患者自身抗体的调节作用及相关分析[J].中国神经免疫和神经病学杂志,2000;7(4):234-236.
[56] Ragheb S,Lisak RP.The thymus and myasthenia gravis[J].Chest Surg Clin N Am,2001;11(2):311-327.
[57] Castleman B.The pathology of the thymus gland in myasthenia gravis[J].Ann N Y Acad Sci,1996;135(1):496.
[58] Levinson AI,Wheatley LM.The thymus and the pathogenesis of myasthenia gravis[J].Clin Immunol Immunopayhol,1996;78:1-5.
[59] Zweiman B,Levinson AI,Lisak RP,et al.Phenotypic characterization of thymic B lymphocytes in myasthenia gravis[J]. Clin Immunol,1989;9(3):242.
[60] Sommer N,Willcox N,Harcourt GC,et al.Myasthenia thymos and thymoma are selectively enriched in acetylcholine receptor reactive T cells[J].Ann Neurol,,1990;28:312-319.
[61] Fujii Y,Hashimoto J,Monden Y,et al.Specific activation of lymphocytes against acetylcholine receptor in myasthenia gravis[J].J Immunol,1986;136(3):887.
[62] 岳岚,柴莹,沈钢,等.胸腺生发中心及 Bcl-2 蛋白表达水平与获得性自身免疫性重症肌无力的关系[J]. 中国实用内科杂志,2001;21(4):228.
[63] Sommer N,Willcox N Harcourt GC,et al.Myasthenia thymos and thymoma are selectively enriched in acetylcholine receptor reactive T cells[J].Ann Neurol,1990;28:312.
[64] Oosterhuis HJ,Kuks JB.Myasthenia gravis and myasthenic syndromes in the rat[J].Curr Opin Neurol Neurosurg,1992;5(5):638.
[65] Shiono H,Fujii Y,Okumura M,et al.Failure to down regulate Bcl-2 protein in thymic geminal center B cell in myasthenia gravis[J].Eur J Immunol,1997;27(4):805.
[66] Onodera J,Nakamura S,Nagano I,et al.Upregulation of Bcl-2 protein in the myasthenic thymus[J].Ann Neurol,1996;39(4):521
[67] Shiono H,Fujii Y,Okumura M,et al. Failure to down regulate Bcl-2 protein in thymic geminal center B cell in myasthenia gravis[J].Eur J Immunol,1997;27(4):805-809.
[68] 张清勇,赵国强,杜英,等. 重症肌无力患者胸腺组织中 P1O、Bcl-2 和 Fas mRNA的表达[J].郑州大学学报,2005;40(1):8.
[69] 沈钢,柴建,岳岚. 重症肌无力患者胸腺组织中 Bcl-2 和 Fas 表达水平的研究[J].浙江医学,2005;27(6):415-416.
[70] Horiki T,Inoko H,Moriuchi J,et al.Combinations of HLA-DPB1and HLA-DQB1alleles determine susceptibility to early-onset myasthenia gravis in Japan[J].Autoimmunity,1994;19:49-54.
[71] Giraud M,Beaurain G,Eymard B,et al.Genetic control of autoantibody expression in autoimmune myasthenia gravis:role of the self-antigen and of HLA-linked loci[J].Genes Immun,2004;5:398-404.
[72] Donez B,Ozakbas S,Oktem MA,et al. HLA genotypes in Turkish patients with myasthenia gravis:comparison with multiple sclerosis patients on the basis of cilinical subtypes and demographic features.Hnm Immunol,2004;65:752-757.
[73] Shinomiya N,Nomura Y,Segawa M.A variant of childhood-onset myasthenia gravis:HLA typing and clinical characteristics in Japan[J].Clin Imnunol,2004;110:154-158.
[74] Dawkins R.Association between myasthenia gravis and HLA Bw46 ,Bfs,C4A4,C4B2,DR9 in Chinese.In:Bo Duponted[M].Immunobiology of HLA,New York:Springer-verlag,1987,437-439.
[75] 杜可明,张克雄. HLA-Ⅱ基因多肽性与重症肌无力的易感性[J].国外医学遗传学分册,2000;23:11-13.
[76] Garchon HJ.Genetics of autoimmune myasthenia gravis,a model for antibody-meiated autoimmunity in man [J].J Autoimmun,2003;21:105-110.
[77] 许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000,139-151.
[78] 解燕春,李承晏.重症肌无力治疗新进展[J].临床内科杂志,2005;22(6):374-376. [79 ]Richman DP,Agius MA.Treatment of autoimmune myasthenia gravis[J].Neurology,2003;61:1652-1661.
[80] Richman DP,Agius MA. Treatment principles in the management of autoimmune myasthenia gravis[J].Ann NY Acad Sci,2003;998:473-480.
[81] Keesey JC.Clinical evaluation and management of myasthenia gravis[J].Muscle Nerve,2004;29:484-505.
[82] Clafaloni E,Nikhar NK,Massey JM,et al.Retrospective analysis of the use of cyclosporine in myasthenia gravis[J]. Neurology,2000;55:448-450.
[83]龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,44.
[84] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,568-577.
[85] 黄自立.中医百家医论荟萃[M],重庆:重庆出版社,1988,613.
[86] 黄自立.中医百家医论荟萃[M],重庆:重庆出版社,1988,614.
[87] 张介宾.景岳全书[M],上海:上海科学技术出版社,1959,556-558.
[88] 叶天士.临证指南医案[M],上海:上海人民出版社,1959,518-526.
[89] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,78.
[90] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,412.
[91] 龙伯坚,龙式昭.黄帝内经集解[M],天津:天津科学技术出版社,2004,151.
[92] 张慧.痿证论治,重在脾肾-胡建华临床经验[J].上海中医药杂志,1998; (7):7-8.
[93] 林丽,曹惠芬.孟如教授辨治重症肌无力经验举要[J].云南中医学院学报,1998;21(4):34-35.
[94] 陈济东,陈贯一.辨证治疗重症肌无力 216 例[J]. 浙江中医学院学报,2003;27(1):34-35.
[95] 将方建,吴青,陈钢,等.“强力方” 治疗重症肌无力临床观察及对外周血淋巴细胞表型的影响[J]. 上海中医药杂志,1999;(7):9-11.
[96] 段竹联,周增荣.补中益气汤和金匮肾气丸加减治疗重症肌无力之体会[J].现代中医药,2003;(6):48-49.
[97] 徐杰.温运法治疗眼肌型重症肌无力 65 例[J].湖北中医杂志,1988;(4):19-20.
[98] 李忠林.中医药治疗重症肌无力的临床观察[J].天津中医,1996;13(4):21-23.
[99] 韩涛.中西医结合治疗重症肌无力研究探要[J].中医药学刊,2003;21(1):139-140.
[100] 许风全,陈金亮,胡军勇,等.重肌灵系列制剂治疗重症肌无力 300 例[J].中国中医药科技,2001;8(5):333-335.
[101] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,384.
[102] 陈玉春.人参、附子与参附汤免疫调节作用初探[J].中成药,1994;16(8):30-31.
[103] 董群,鲁义东,吴敏毓,等.芪附汤及其组方对阳虚小鼠免疫功能的影响[J].中国实验方剂学杂志,1999;5(3):15-17.
[104] 董淳,徐群英. 芪附汤及其组方对免疫抑制小鼠免疫功能的影响[J].中国中医药信息杂志,2001;8(9):39-41.
[105] 吴伟康.四逆汤方药对注射大剂量氢化可的松大鼠血清 IgG 水平影响的初步观察[J].中医杂志,1988;29(10):59.
[106] 王米渠,严石林,李炜弘,等.寒性中药对 SD 大鼠的实验研究[J].浙江中医学院学报,2002;26(6):43-45.
[107] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,528-530.
[108] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,537-539.
[109] 梁华平,张艳.黄芪多糖调节创伤小鼠白介素 2 及白介素受体基因表达的实验研究[J].中医药学报,1995;(3):27.
[110] 洪介民,邱健行,胡祖光.黄芪多糖在体外对小鼠粒巨噬细胞系祖细胞的影响[J]. 中医药学报,1997;(6):44.
[111] 冯浚志,赵国平.当归的免疫药理研究进展[J].福建中医药,2003;34(3):49-51.
[112] 冯景奇,柳钟勋,左增艳,等.当归多糖及当归内酯对小鼠细胞免疫功能的影响[J].中国免疫学杂志,1998;14(4):279-282.
[113] 刘景田,党小军,张洁.中药多糖增强淋巴细胞免疫效应与机制研究[J]. 中国药学杂志,1999;34(12):807-809.
[114] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,542.
[115] 中华人民共和国药政管理局.现代实用本草[M],北京:人民卫生出版社,1997,248.
[116] 王学廷,王建刚,常永超,等.山萸肉对小鼠免疫功能的影响[J].洛阳医专学报,1994;13(3):135.
[117] 董昆山,王秀琴,董一凡.现代临床中药学[M],北京:中国中医药出版社,1998,584.
[118] 王浴生,邓文龙,薛春生.中药药理与应用[M],北京:人民卫生出版社,1998,895.
[119] 卞长武,王东荣,郭文来,等.莪术对小鼠免疫功能的影响[J].中国中医药信息杂志,1989;4(2):29.
[120] Osbima M, Pachner AR,Atassi MZ.Molprofile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG susceptible and non- susceptible mouse strains after different periods of immunization with the receptor[J]. Immunology,1994;31(11):833-843.
[121] Lennon VA,Lindstrom JM,Seybold ME,et al.Experimental autoimmune myasthenia:a model 0f myasthenia gravis in rats and guinea pigs[J].J EXP Med,1975 ;141:1365-1372.
[122] Baggi F,Annomm A,Ubiali F,et al.Breakdown of tolerance to a self-peptide of acetylcholine receptor –subumit induces experimental myasthenia gravis in rats[J]. J Immunol,2004;172(4):2697-2703.
[123] Hoedernaekers AC,Verschnuren JJ,Spaas F,et al.Agerelated susceptibility to experimental auoimmune myasthenia gravis:immunolgical and electrophysiological aspecs. Muscle Nerve,1997,20(9):1091-1101.
[124] Lee KW,Lee SH,Kim Hj,et al. Experimental auoimmune myasthenia gravis and CD5+ B lymphocyte expression.J Korean Med Sci,1999,14(1):75-79.
[125] Wang HB,Shi Fd,Li H,et al.Anti CTLA-4 antiody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol,2001,166(10):6430-6436.
[126] Peas-Rozner M,Mozes E.The nature of the active supression of responses associated with experimental auoimmune myasthenia gravis by a dual altered peptide ligad administered by different routes.Proc Natl Acad SciUSA,2001,98(22):12642-12647.
[127] Scelasa,Frost M,Valderrama R,et al.Prevention and treatment of experimental auoimmune myasthenia gravis with anti-rabbit thymcte serum and gammaglobulin in rabbits.Pathobiology,1995,63(3):168-174.
[128] Goluszko E,Hjelmstrom P,Deng C,et al.Lymphotoxiu-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis.J Neuroimmunol,2001;113:109-118.
[129] Vincent A,Jacobson L,Shillitoc P.Response to human acetylcholine receptor α138-167:determinant spreading intiates autoimmunity to self-antigen in rabbits.Immunol lett,1994;39(10):269-275.
[130] 杨丽,程焱.乙酰胆碱受体α亚单位 125-147 段多肽之实验性自身免疫性重症肌无力.中华神经科杂志,2003;36(1):32-34.
[131] Wang ZY,Karachunski PI,Howard JF Jr,et al.Myasthenia gravis in SCID mice grafted with Myasthenia patient lymphocytes.Neurology,1999;52(3):484-497.
[132] Schoubeck S,Padberg F,Hohlfeld R,et al.Transplantation of thymic autoimmune microenvironment to serve combined immunodeficiency mice.A new model of myasthenia gravis.J Clin Invest,1992;90(1):245-250.
[133] 刘降光,王晓辉,张宏,等.实验性自身免疫性重症肌无力动物模型.中国神经免疫和神经病学杂志,2005;12(2):90-93.
[134] 许贤豪.神经免疫学,武汉:湖北科学技术出版社,2000,145.
[135] 龚非力. 基础免疫学,武汉:湖北科学技术出版社,1998,18.
[136] 张栩,孙兆林,从志强,等.重症肌无力病人外周血单个核细胞 TGF-? 及 IL-6水平测定.青岛大学医学院学报,2003;39(4):386-387.
[137] 李罗清,孙圣刚,徐金枝,等.白细胞介素-6 与重症肌无力患者临床特点的关系.临床神经病学杂志,2005;18(1):19-21.
[138]Cohen-Kaminsky S,Devergne O,Delatre Related Articles,et al.Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially in volved in thymic myperplasia.Eur Cytokin Netw,1993;4(2):121-132.
[139] 徐江龙.肿瘤坏死因子与重症肌无力.中国临床神经科学,2004;12(3):326-327.
[140] 姜广建,马立人,王润田,等. 重症肌无力患者 T 细胞亚群和 TNF-α 检测及临床意义.临床荟萃,2002;17(21):246.
[141] 胡军,阮丽荣,张清勇,等. 重症肌无力患者外周血单个核细胞 Fas 及血清 sFas、TNF 检测.郑州大学学报(医学版),2005;40(1):4-6.
[142] 闫晓波,王维治,韩威. 重症肌无力 cICAM-1 及 TNF-α水平的检测.中国神经免疫学和神经病学杂志,2002;9(2):80.
[143] Huang DR,Priskanen R,Matell G,et al.Tumor necrosis factor-alpha polymorphism and secretion in myasthenia gravis.Neuroimmunol,1999;94(1):165-171.
[144] Confalonieri P,Antozzi C,Comelio F,et al.Immune activation in myasthenia gravis:soluble interleukin-2 receptor ,interferon-gamma and tumor necrosis factor-alpha levels in patients serum.J Neuroimmunol,1993;48(1):33-36.
[145] 程卫东,张庆举.血清可溶性白介素-2 受体滴度与重症肌无力肌群受累程度的相关性研究.临床神经科病学杂志,2004;17(4):253-254.
[146] 许良中,杨文涛.免疫组织化学反应结果的判定标准.中国癌症杂志,1996;6(4):229-230.
[147] Gowans JL,Knight.The route of recirculation of lymphocytes in the rat.Proc R Soc London B,1964;159:257.
[148] Naparstek Y,Ben-Nun A,Holosshitz J,et al.T lymphocytelines producing or vaccinating against autoimmune encephalomyelitis(EAE). Functioal activation induces peanut agglutienin rceptors and accumulation in the brain and thymus of line cells.Eur J Immunol,1993,13(5):418.
[149] Naparstek Y,Holoshitz J,Eissenstein S,et al.Effector T lymophocyte line cells in igrate to the thymus and persist there.Nature,1982;300(5889):262.
[1] 许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000;119.
[2] 中国医学科学院皮肤病研究所雷公藤研究小组.雷公藤多甙治疗某些皮肤病的研究.中华皮肤科杂志,1982;15:199.
[3] 李作孝,张泽兰,谭华,等.重症肌无力患者雷公藤多甙治疗后周围血细胞免疫功能变化的研究.四川医学,2001;22(2):124-125.
[4] 李作孝,熊先骥,张泽兰,等. 重症肌无力患者雷公藤多甙治疗前后周围血自然杀伤细胞含量变化的研究.临床神经学杂志,1999;12(4)216-218.
[5] 陈正君. 雷公藤多甙对重症肌无力患者血清 sIL-2R 水平的影响.邯郸医学高等专科学校学报,2001;14(2):95-96.
[6] 李作孝,谭华,熊先骥,等. 雷公藤多甙辅助治疗重症肌无力临床疗效及对血清 IL-6 的影响.中国中西医结合杂志,2002;22(3):175-176.
[7] 徐冬波,蒋方建,李庚和,等.强力方和黄芪治疗实验性自身免疫性重症肌无力的机理.中医药研究,2000;16(2):41-44.
[8] 赖成虹,李作孝,刘广益.苏木免疫抑制作用的研究进展.医学综述,2004;10(10):635-636.
[9] 赖成虹,李作孝,荣本兵,等.苏木醇提物治疗小鼠实验性重症肌无力的研究.中华神经医学杂志,2005;4(7):669-671.
[10] 蒋方建,吴青,陈钢,等.“强力方”治疗重症肌无力临床观察及对外周血淋巴细胞表型的影响.上海中医药杂志,1999;(7):9-11.
[11] 徐冬波,蒋方建,李庚和,等.强力方对实验性自身免疫性重症肌无力细胞因子含量的影响.上海中医药杂志,2000;10:40-43.
[12] 徐冬波,蒋方建,李庚和,等. 强力方和黄芪治疗实验性自身免疫性重症肌无力的机理.中医药研究,2000;16(2):41-44.
[13] 刘萍,张静生,韩波,等.黄芪复方对重症肌无力 IFN-γ及其 mRNA 表达的影响.中医药学刊,2004;22(11):2021-2022.
[14] 刘萍,张静生,郑菲,等.黄芪复方对重症肌无力患者血清乙酰胆碱受体抗体水平的影响.中国神经免疫和神经病学杂志,2005;12(2):76-77.
[15] 许风全,陈金亮,平阳,等.重肌灵片治疗ⅡA 型重症肌无力的临床研究.北京中医药大学学报,2004;11(4):4-8.
[16] 王旭丹,周勇,韩涛,等.重肌灵片对实验性重症肌无力的影响.上海免疫学杂志,2003;23(5):339-342.
[17] 王旭丹,杨颖袁学勤,等.重肌灵片在重症肌无力小鼠模型 T 细胞活化中的作用.现代免疫学,2005;25(5):411-414.
[18] 张志慧,韩涛.重肌灵对大鼠腹腔巨噬细胞吞噬功能以及 IL-1 诱生的影响[J].中医药学刊,2003;21(7):1129-1130.
[19] 王静,周勇,王旭丹,等.中药重肌灵片体内对 EAMG 大鼠 IFN-γ、IL-4、TGF-β水平的影响.中国免疫学杂志,2004;20(1):63-66.
[60] 黄坤强,王灵萍,尚尔寿,等.复肌宁胶囊治疗重症肌无力 70 例临床观察[J].中国中西医结合杂志,1998;18(12):743-744.
[21] 王曙辉,杨明山.温肾健脾益气活血法治疗重症肌无力 52 例[J].新中医,1999;31(5):33-34.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |